Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Bussel

Showing results (151-160 of 262) with videos related to

Pageof 27
Sort By:
Platelets|July 9, 2019
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonistsLamya Garabet, Waleed Ghanima, Marit Hellum, et al.
Blood|November 22, 2012
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyMansoor N Saleh, James B Bussel, Gregory Cheng, et al.
The Cochrane Database of Systematic Reviews|May 13, 2011
Antenatal interventions for fetomaternal alloimmune thrombocytopeniaRachel Rayment, Susan J Brunskill, Peter W Soothill, et al.
Health and Quality of Life Outcomes|February 24, 2007
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validationSusan D Mathias, James B Bussel, James N George, et al.
Clinical Therapeutics|August 19, 2007
A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trialSusan D Mathias, James B Bussel, James N George, et al.
Obstetrics and Gynecology|August 2, 2007
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trialRichard L Berkowitz, Martin L Lesser, Janice G McFarland, et al.
Obstetrics and Gynecology|October 22, 2011
Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratificationLuis D Pacheco, Richard L Berkowitz, Kenneth J Moise, et al.
Platelets|January 13, 2023
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort studyAlexander Åkesson, James B Bussel, Myriam Martin, et al.
American Journal of Hematology|September 26, 2022
Romiplostim use in pregnant women with immune thrombocytopeniaJames B Bussel, Nichola Cooper, Tatiana Lawrence, et al.
Obstetrics and Gynecology|January 6, 2006
Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopeniaRichard L Berkowitz, E Anders Kolb, Janice G McFarland, et al.
Pageof 27

Showing results (151-160 of 262) with videos related to

Sort By:
Pageof 27
Platelets|July 9, 2019
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonistsLamya Garabet, Waleed Ghanima, Marit Hellum, et al.
Blood|November 22, 2012
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyMansoor N Saleh, James B Bussel, Gregory Cheng, et al.
The Cochrane Database of Systematic Reviews|May 13, 2011
Antenatal interventions for fetomaternal alloimmune thrombocytopeniaRachel Rayment, Susan J Brunskill, Peter W Soothill, et al.
Health and Quality of Life Outcomes|February 24, 2007
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validationSusan D Mathias, James B Bussel, James N George, et al.
Clinical Therapeutics|August 19, 2007
A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trialSusan D Mathias, James B Bussel, James N George, et al.
Obstetrics and Gynecology|August 2, 2007
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trialRichard L Berkowitz, Martin L Lesser, Janice G McFarland, et al.
Obstetrics and Gynecology|October 22, 2011
Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratificationLuis D Pacheco, Richard L Berkowitz, Kenneth J Moise, et al.
Platelets|January 13, 2023
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort studyAlexander Åkesson, James B Bussel, Myriam Martin, et al.
American Journal of Hematology|September 26, 2022
Romiplostim use in pregnant women with immune thrombocytopeniaJames B Bussel, Nichola Cooper, Tatiana Lawrence, et al.
Obstetrics and Gynecology|January 6, 2006
Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopeniaRichard L Berkowitz, E Anders Kolb, Janice G McFarland, et al.
Pageof 27